KR20260016617A - Sarm1의 억제제 - Google Patents
Sarm1의 억제제Info
- Publication number
- KR20260016617A KR20260016617A KR1020267002225A KR20267002225A KR20260016617A KR 20260016617 A KR20260016617 A KR 20260016617A KR 1020267002225 A KR1020267002225 A KR 1020267002225A KR 20267002225 A KR20267002225 A KR 20267002225A KR 20260016617 A KR20260016617 A KR 20260016617A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- ring
- nitrogen
- mmol
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immunology (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069408P | 2020-08-24 | 2020-08-24 | |
| US63/069,408 | 2020-08-24 | ||
| US202163142398P | 2021-01-27 | 2021-01-27 | |
| US63/142,398 | 2021-01-27 | ||
| PCT/US2021/047093 WO2022046606A1 (en) | 2020-08-24 | 2021-08-23 | Inhibitors of sarm1 |
| KR1020237009643A KR102918550B1 (ko) | 2020-08-24 | 2021-08-23 | Sarm1의 억제제 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237009643A Division KR102918550B1 (ko) | 2020-08-24 | 2021-08-23 | Sarm1의 억제제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20260016617A true KR20260016617A (ko) | 2026-02-03 |
Family
ID=77775005
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267002225A Pending KR20260016617A (ko) | 2020-08-24 | 2021-08-23 | Sarm1의 억제제 |
| KR1020237009643A Active KR102918550B1 (ko) | 2020-08-24 | 2021-08-23 | Sarm1의 억제제 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237009643A Active KR102918550B1 (ko) | 2020-08-24 | 2021-08-23 | Sarm1의 억제제 |
Country Status (22)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3123215C (en) | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with neuroprotective agents |
| EP4192828A1 (en) | 2020-08-04 | 2023-06-14 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| WO2022060812A1 (en) | 2020-09-16 | 2022-03-24 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| KR20240041987A (ko) | 2021-07-28 | 2024-04-01 | 누라 바이오, 인크. | Sarm1 억제제로서 치환된 피리딘 유도체 |
| IL318437A (en) * | 2022-07-21 | 2025-03-01 | Amylyx Pharmaceuticals Inc | Compositions containing oligonucleotides, and methods of using them |
| IL321043A (en) * | 2022-12-15 | 2025-07-01 | Sironax Ltd | SARM1 modulators, their preparations and uses |
| WO2024158775A1 (en) | 2023-01-24 | 2024-08-02 | Disarm Therapeutics, Inc. | Pyridazines as sarm1 inhibitors |
| CN121399112A (zh) * | 2023-04-27 | 2026-01-23 | 维泰瑞隆有限公司 | Sarm1调节剂、其制备和用途 |
| CN119219603A (zh) * | 2023-06-28 | 2024-12-31 | 科辉智药(深圳)新药研究中心有限公司 | Sarm1酶活性抑制剂及其用途 |
| WO2025049184A1 (en) | 2023-08-25 | 2025-03-06 | Eli Lilly And Company | (s)-3-((6-fluoropyridin-3-yl)methyl)-1-(5-(pyridin-4-yl)-4h-1,2,4-triazol-3-yl)piperidin-2-one benzenesulfonate |
| EP4766702A1 (en) * | 2023-08-25 | 2026-07-01 | F. Hoffmann-La Roche AG | Pyrazole derivatives used as MRSA inhibitors useful for the treatment of neurodegenerative disorders |
| WO2025076088A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Lactams for use as sarm1 inhibitors |
| WO2025076017A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Carbamates for use as sarm1 inhibitors |
| TW202545928A (zh) | 2024-01-25 | 2025-12-01 | 比利時商優稀美生物醫藥股份有限公司 | 吡咯啶酮衍生物 |
| WO2026104394A1 (en) | 2024-11-13 | 2026-05-21 | UCB Biopharma SRL | Pyrrolidinone derivatives inhibitors of sarm1 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11193281A (ja) | 1997-10-27 | 1999-07-21 | Takeda Chem Ind Ltd | アデノシンａ３受容体拮抗剤およびチアゾール化合物 |
| US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| AU2003288956A1 (en) | 2002-10-30 | 2004-06-07 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| AU2003300099A1 (en) | 2003-01-02 | 2004-07-29 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP1751133B1 (en) | 2004-04-28 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| MX2007007330A (es) | 2004-12-16 | 2007-10-04 | Vertex Pharma | Piridonas de utilidad como inhibidores de quinasas . |
| JP5244591B2 (ja) | 2006-06-28 | 2013-07-24 | あすか製薬株式会社 | ピリジルイソオキサゾール誘導体 |
| KR20090057032A (ko) | 2006-09-21 | 2009-06-03 | 노파르티스 아게 | 사이토카인 매개 질환의 치료에 유용한 피롤 유도체 |
| JP2011506560A (ja) | 2007-12-20 | 2011-03-03 | ノバルティス アーゲー | Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体 |
| WO2009080705A2 (en) | 2007-12-20 | 2009-07-02 | Novartis Ag | Bis-thiazole derivatives, process for their preparation and their use as medicaments |
| TW201004941A (en) | 2008-07-16 | 2010-02-01 | Wyeth Corp | Alpha7 nicotinic acetylcholine receptor inhibitors |
| US8785468B2 (en) | 2009-02-13 | 2014-07-22 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
| WO2012178022A2 (en) | 2011-06-24 | 2012-12-27 | University Of Massachusetts | Therapeutic applications targeting sarm1 |
| US9284310B2 (en) | 2012-11-03 | 2016-03-15 | Boehringer Ingelheim International Gmbh | Inhibitors of cytomegalovirus |
| EP2934536B1 (en) | 2012-12-19 | 2017-09-27 | Merck Sharp & Dohme Corp. | FACTOR IXa INHIBITORS |
| RU2570907C2 (ru) | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. |
| WO2015084936A1 (en) | 2013-12-04 | 2015-06-11 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| EP4091622A1 (en) | 2016-08-16 | 2022-11-23 | Henry Ford Health System | Compositions for the treatment of chemotherapy-induced neuropathic pain |
| EP3515426A1 (en) | 2016-09-24 | 2019-07-31 | Washington University | INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF |
| WO2018107056A1 (en) | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | 1,3-substitued pyrazole compounds useful for reduction of very long chain fatty acic levels |
| WO2018114663A1 (de) | 2016-12-22 | 2018-06-28 | Bayer Cropscience Aktiengesellschaft | Substituierte azolylpyrrolone und azolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| BR112019012822A2 (pt) * | 2016-12-22 | 2019-11-26 | Bayer Ag | 1,2,4-tiadiazolilpirrolonas e 1,2,4-tiadiazolil-hidantoínas e sais das mesmas e uso das mesmas como herbicidas |
| BR112020012651A2 (pt) | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | compostos derivados de aril-bipiridina amina como inibidores da fosfatidilinositol fosfato quinase, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos |
| EP3801503A4 (en) * | 2018-06-07 | 2021-12-08 | Disarm Therapeutics, Inc. | INHIBITORS OF SARM1 |
| CA3102645A1 (en) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| JP7478142B2 (ja) | 2018-06-07 | 2024-05-02 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１阻害剤 |
| EP3919055A4 (en) | 2019-01-30 | 2022-11-09 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| US12624025B2 (en) | 2019-06-06 | 2026-05-12 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| JP7319395B2 (ja) | 2019-06-14 | 2023-08-01 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１の阻害剤 |
| KR20220035939A (ko) | 2019-07-22 | 2022-03-22 | 바이엘 악티엔게젤샤프트 | 살충제로서의 5-아미노-치환된 피라졸 및 트리아졸 |
| WO2021050913A1 (en) | 2019-09-12 | 2021-03-18 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| US20230029266A1 (en) | 2019-11-05 | 2023-01-26 | Dermira, Inc. | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders |
| AU2021206651B2 (en) | 2020-01-07 | 2024-02-22 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| WO2021207308A1 (en) | 2020-04-09 | 2021-10-14 | Disarm Therapeutics, Inc. | Condensed pyrazole derivatives as inhibitors of sarm1 |
| CA3174321A1 (en) | 2020-04-09 | 2021-10-14 | Disarm Therapeutics, Inc. | Indazole derivatives as inhibitors of sarm1 |
| EP4192828A1 (en) | 2020-08-04 | 2023-06-14 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
-
2021
- 2021-08-20 TW TW111144632A patent/TW202334117A/zh unknown
- 2021-08-20 TW TW113140249A patent/TWI904906B/zh active
- 2021-08-20 TW TW110130799A patent/TWI786777B/zh active
- 2021-08-23 WO PCT/US2021/047093 patent/WO2022046606A1/en not_active Ceased
- 2021-08-23 CR CR20230113A patent/CR20230113A/es unknown
- 2021-08-23 CN CN202610495345.1A patent/CN122404291A/zh active Pending
- 2021-08-23 UA UAA202300576A patent/UA130657C2/uk unknown
- 2021-08-23 BR BR112023002575A patent/BR112023002575A2/pt unknown
- 2021-08-23 KR KR1020267002225A patent/KR20260016617A/ko active Pending
- 2021-08-23 IL IL300586A patent/IL300586A/en unknown
- 2021-08-23 CA CA3313757A patent/CA3313757A1/en active Pending
- 2021-08-23 PE PE2023000530A patent/PE20230737A1/es unknown
- 2021-08-23 KR KR1020237009643A patent/KR102918550B1/ko active Active
- 2021-08-23 US US17/408,956 patent/US12043613B2/en active Active
- 2021-08-23 MX MX2023002256A patent/MX2023002256A/es unknown
- 2021-08-23 EP EP21770372.7A patent/EP4200293A1/en active Pending
- 2021-08-23 AU AU2021333558A patent/AU2021333558C1/en active Active
- 2021-08-23 JP JP2023513172A patent/JP7349046B2/ja active Active
- 2021-08-23 CA CA3189181A patent/CA3189181A1/en active Pending
- 2021-08-23 NZ NZ797733A patent/NZ797733A/en unknown
-
2023
- 2023-02-14 ZA ZA2023/01801A patent/ZA202301801B/en unknown
- 2023-02-22 CO CONC2023/0001975A patent/CO2023001975A2/es unknown
- 2023-02-22 CL CL2023000525A patent/CL2023000525A1/es unknown
- 2023-02-23 DO DO2023000038A patent/DOP2023000038A/es unknown
- 2023-02-23 JO JOJO/P/2023/0037A patent/JOP20230037A1/ar unknown
- 2023-02-23 EC ECSENADI202312981A patent/ECSP23012981A/es unknown
- 2023-09-08 JP JP2023145779A patent/JP7756130B2/ja active Active
-
2024
- 2024-05-21 AU AU2024203373A patent/AU2024203373B2/en active Active
- 2024-06-19 US US18/747,889 patent/US20240376083A1/en active Pending
-
2026
- 2026-07-02 AU AU2026205227A patent/AU2026205227A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102918550B1 (ko) | Sarm1의 억제제 | |
| CN115175900B (zh) | Sarm1的抑制剂 | |
| CN114728007B (zh) | Sarm1的抑制剂 | |
| CN116075511B (zh) | 作为sarm1抑制剂的稠合吡唑衍生物 | |
| JP7319395B2 (ja) | Ｓａｒｍ１の阻害剤 | |
| CN115916764B (zh) | 作为sarm1抑制剂的吲唑衍生物 | |
| CN116568678B (zh) | Sarm1的苯并吡唑抑制剂 | |
| JP7478142B2 (ja) | Ｓａｒｍ１阻害剤 | |
| JP2022534544A (ja) | Ｓａｒｍ１の阻害剤 | |
| HK40075925A (en) | Inhibitors of sarm1 | |
| EA048703B1 (ru) | Ингибиторы sarm1 | |
| BR122025022748A2 (pt) | Inibidores de sarm1, composições que os compreendem, usos dos mesmos, métodos para inibir sarm1, e combinações | |
| CN116940569A (zh) | Sarm1抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| A18 | Application divided or continuation or continuation in part accepted |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |